Oral Medication | Page 6 of 11

FDA Approves New Type 2 Diabetes Combination Medication Jentadueto

The FDA has approved Eli Lilly and Boehringer Ingelheim's new type 2 diabetes treatment Jentadueto (linagliptin/metformin hydrochloride), which combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet...

FDA Requests Additional Data on Type 2 Diabetes Drug Dapagliflozin

The FDA has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapagliflozin for the treatment of type 2 diabetes in adults submitted by Bristol-Myers Squibb Company and AstraZeneca...

Can Metformin Reduce Cardiovascular Risk in Type 1 Diabetes Patients?

JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with type 1 diabetes...

Type 2 Diabetes Drug ONGLYZA Approved for Sale in Europe

The European Commission has approved Bristol-Myers Squibb Company and AstraZeneca's ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycemic) control in adult patients with type 2 diabetes...

FDA Approves New Combination Drug, Juvisync, for Treatment of Type 2 Diabetes

The FDA has approved a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA, with the cholesterol-lowering medication ZOCOR (simvastatin). The new drug, produced by Merck, known as MSD outside the United States and Canada, will be...

Takeda Launches New Type 2 Diabetes Combination Drug

Takeda Pharmaceutical announced the launch of LIOVEL®, a fixed dose combination tablet of NESINA® (alogliptin) and ACTOS® (pioglitazone HCl) for treatment of type 2 diabetes. LIOVEL is a tablet taken orally once daily and has two dosage strengths

Adding ONGLYZA to Insulin in Adults with Type 2 Diabetes Found Effective

Results of an investigational Phase 3b clinical study, presented by Bristol-Myers Squibb Company and AstraZeneca at the 47th European Association for the Study of Diabetes (EASD), have shown that adding ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes...

Lilly’s New Type 2 Diabetes Drug Receives EU Approval

The new type 2 diabetes drug Trajenta (linagliptin 5 mg film-coated tablets) received Marketing Authorization from the European Commission for the treatment of type 2 diabetes. The European Commission has approved linagliptin in combination with metformin and metformin plus sulfonylurea. Linagliptin is also approved for use as monotherapy in patients...

Takeda Resubmits New Type 2 Diabetes Drugs for FDA Approval

Takeda has resubmitted two New Drug Applications (NDA) to the U.S. Food and Drug Administration (FDA) for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone, approved in 1999, for the treatment of type 2 diabetes, in a single tablet...

FDA Advisory Committee Votes Against Type 2 Diabetes Drug Dapagliflozin

The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting reached a decision regarding the New Drug Application, by The Bristol-Myers Squibb Company and AstraZeneca for the investigational compound dapagliflozin for treatment of type 2 diabetes...

Category: Oral Medication